item management s discussion and analysis of financial condition and results of operations the results for the year ended december  have been restated from prior periods to reflect the merger of shire pharmaceuticals group plc and roberts pharmaceutical corporation as if the merger had occurred on january  the following discussion should be read in conjunction with the company s consolidated financial statements and related notes appearing elsewhere in this report 
results of operations years ended december  and overview for the year ended december   total revenue increased by to million  compared to million in fiscal this increase was primarily the result of an increase in product sales 
product sales in the us continue to represent a significant percentage of worldwide sales  increasing to in from in net income for the year ended december  was million as compared to a net loss in of million 
the prior year results include approximately million in non recurring asset impairment and restructuring charges and million for merger transaction expenses 
the company manages and controls the business on geographic lines 
the three reportable segments are the us  europe and the rest of the world 
additional information regarding segments is provided in note to the consolidated financial statements 
product sales the following table presents the company s net product sales by operating segment product sales by segment change change m m m us europe rest of world total product sales for the year ended december   total product sales increased by to million  compared to million in the prior year 
of the company s total product sales  approximately related to adderall and dextrostat  the company s products marketed in the us for the treatment of adhd 
on a combined basis  these products increased their share of the total us adhd prescriptions written from in december to in december cost of sales for the year ended december  cost of sales amounted to of product sales as compared to in overall  the higher margin products such as adderall  pentasa  and agrylin have continued to grow at a faster rate than the lower margin products  contributing a higher proportion of sales in the year ended december  than in the preceding year 
research and development research and development expenditure increased from million in to million in  representing an increase of 
this increase reflects the significant portion of development projects at phase ii or later where development costs are higher 
as a proportion of total revenues research and development expenditure is 
selling  general and administrative expenses selling  general and administrative expenses  excluding the effects of a stock option compensation charge of million million  increased by million from million in to million in fiscal as a percentage of product sales  selling  general and administrative expenses fell by to 
increases in sales and marketing expenses in the us  including the recruitment of new sales representatives in the fourth quarter of the year  have been more than offset by merger cost savings and a one off settlement from pending litigation with rhone poulenc rorer  inc a significant component of selling  general and administrative expenses are depreciation and amortization charges  which increased from million in to million in interest income and expense in the year ended december  the company received interest income of million compared with million in this decrease reflects the average cash balances held during the year 
cash and cash equivalents during the early part of were lower than in the comparative period because of the cash outflows associated with the group s restructuring activities 
interest expense increased from million in to million in  reflecting an increase in underlying rates of interest of approximately and a full year s interest change on the convertible loan notes 
income taxes for the year ended december   income taxes increased million from million to million 
the company s effective tax rate in was 
the company has recorded net deferred tax assets of approximately million december  million 
realization is dependent upon generating sufficient taxable income to utilize such assets 
although realization on these tax assets is not assured  management believes it is more likely than not that the deferred tax assets will be realized 
years ended december  and overview on december   shire and roberts merged in a tax free exchange of shares 
shire exchanged adss for each common share of roberts 
this transaction was accounted for as a pooling of interests 
merger transaction expenses and merger related restructuring costs totaling million are reflected in shire s results of operations 
total revenues for the year ended december   total revenue increased by to million  compared to million in fiscal this increase was primarily the result of an increase in product sales 
product sales for the year ended december   total product sales increased by to million  compared to million in the prior year 
of the company s total product sales  related to adderall and dextrostat for the treatment of adhd 
on a combined basis  these products increased their share of the total us adhd prescriptions written from in december to in december other significant contributors to the increase in product sales in were the us marketed products pentasa  carbatrol and agrylin 
the company acquired pentasa  licensed for the treatment of ulcerative colitis  in the second quarter of  and recorded sales of million in compared to million in carbatrol increased its share of the total us extended release carbamazepine prescriptions written to at december  from in december and agrylin sales grew over to million in cost of sales for the year ended december  cost of sales amounted to of product sales as compared to in the decrease in cost of sales percentage and corresponding increase in gross margin is attributable to an improved product mix to the faster growth of products with a higher gross margin 
costs and expenses in the company recorded charges totaling million pre tax for asset impairments million  merger related transaction expenses million  restructuring million  loss on product dispositions million and other charges million 
these charges are disclosed separately within operating expenses in the consolidated statements of income 
the company recorded an impairment charge of million to adjust intangible asset values  primarily product rights  to their estimated fair value 
these charges are consistent with the company s accounting policy to review periodically the carrying value of the intangibles and evaluate whether there has been any impairment in the carrying value of those intangibles 
the estimated fair value has been calculated using projected discounted cash flows of the products 
other asset impairments included the write off of inventory held for research and development work and duplicate equipment million  adjustments to the carrying value of the ribogene investment to market value at the year end million  and write down of receivables to their estimated realizable value million 
the components of the restructuring charge are as follows m employee termination costs property in december  the decision was made to close the roberts office facility in eatontown  new jersey and consolidate the sales and marketing operations into the existing shire facility in florence  kentucky and to transfer the research and development activities to shire s facility in rockville  washington 
similarly  roberts sales and marketing operation in the uk was combined with shire s established operation in andover  hampshire 
the office facility in eatontown was closed as of april  while the uk duplicate facility was closed on march  the company completed the sale of the eatontown facility during the third quarter of as a result of the restructuring and elimination of duplicate facilities  the company identified a number of sales and marketing  research and development and administrative positions to be terminated 
these employees were notified of their termination prior to december  the employee termination costs consisted of payments for severance  medical and other benefits  outplacement counseling  acceleration of pension benefits and excise taxes 
the company completed the restructuring program during the fourth quarter of  and the restructuring reserve of million was fully utilized by december  merger cost savings exceeded the company s target of million for the year ended december  research and development research and development expenditure increased from million in to million in  representing an overall increase of 
this increase reflects the significant portion of development projects at phase ii or later where development costs tend to be higher 
selling  general and administrative expenses selling  general and administrative expenses increased million from million in to million in fiscal  primarily due to an increase in size of the us sales force and higher levels of marketing expenditure 
as a percentage of total revenues  selling  general and administrative expenses were constant at approximately in and a significant component of selling  general and administrative expenses is amortization  which increased from million in to million in  due to the addition of the pentasa and agrylin product rights 
interest income and expense in the year ended december  the company received interest income of million compared with million in interest expense increased from million in to million in as a result of a full year s interest expense from the financing of the pentasa acquisition 
income taxes for the year ended december   income taxes increased million from million to million 
the company s effective tax rate in before merger related transaction expenses  restructuring costs and asset impairments was 
the company has recorded net deferred tax assets of approximately million 
realization is dependent upon generating sufficient taxable income to utilize such assets 
although realization on these tax assets is not assured  management believes it is more likely than not that the deferred tax assets will be realized 
liquidity and capital resources the company has financed its operations since inception through private and public offerings of equity securities  the issuance of loan notes  collaborative licensing and development fees  product sales and investment income 
the company s funding requirements depend on a number of factors  including the company s product development programs  business and product acquisitions  the level of resources required for the expansion of marketing capabilities as the product base expands  increased investment in accounts receivable and inventory which may arise as sales levels increase  competitive and technological developments  the timing and cost of obtaining required regulatory approvals for new products  and the continuing revenues generated from sales of its key products 
as of december  and  the company had cash  cash equivalents and marketable securities of million and million  respectively which consisted of immediately available money market fund balances and investment grade securities 
debt in  the company acquired the product rights to pentasa 
the majority of the purchase price was financed through a credit agreement between roberts  credit suisse first boston csfb  previously known as dlj capital funding inc and various other lenders 
under this credit agreement  the merger of shire and roberts constituted a change of control which triggered the acceleration of the repayment of the principal amounts outstanding 
on november   roberts  shire s us subsidiaries and shire entered into an agreement with csfb to replace the existing credit agreement with a million credit facility consisting of a million five year revolving credit facility and a million five year term loan facility 
in connection with the credit facility  the company is subject to certain affirmative and negative covenants and maintenance tests that require the company to maintain a net minimum worth  a specified leverage ratio and a specific coverage ratio 
at december  the company satisfied the aforementioned covenants and maintenance tests 
capital expenditure capital expenditure in the year ended december  of approximately million included the purchase of the group s new head office facility in basingstoke  hampshire  uk for approximately million 
capital expenditures in fiscal of approximately million were principally for the upgrade and expansion of sales and administration functions 
expenditure in of approximately million primarily relates to an upgrade of the manufacturing facility in canada and significant investments in new computer hardware and software 
product acquisitions in may  the company acquired certain european and nordic rights to balsalazide  a treatment for ulcerative colitis  from salix pharmaceuticals ltd 
in the year ended december  the company paid a total of approximately million under the agreement which included million by way of the issue of  new shire ordinary shares 
in november  the company acquired extended distribution and other ancilliary rights for proamatine from nycomed for approximately million  including the ending of royalty obligations to nycomed which enhanced gross margins of this product 
business combinations and divestitures during october and november the company acquired the european sales and marketing subsidiaries from fuisz technologies ltd 
the operations located in france  germany and italy were acquired for approximately million in cash 
a substantial portion of the purchase price was allocated to intangible assets  which are amortized over years 
on december  shire  and roberts merged in a tax free exchange of shares 
this transaction was accounted for as a pooling of interests 
shire exchanged adss for each common share of roberts 
merger transaction expenses and merger related restructuring costs totaled million 
these charges are disclosed separately in operating expenses 
on january  shire disposed of its indianapolis manufacturing plant for a net consideration after expenses of million including a loan note of million 
the net gain of million is included in results of operations 
during november  the company sold the product tigan for million 
the company incurred a loss on disposal of million  which is included within the results of operations 
other commitments information regarding other commitments is disclosed in note to the consolidated financial statements 
foreign currency fluctuations the group s parent company and a number of subsidiary operations are located outside the us as such  the consolidated financial results are subject to fluctuations in exchange rates  particularly those between the us dollar and british pound 
the accumulated foreign currency translation differences are reported within accumulated other comprehensive income 
concentration of credit risk financial instruments that potentially expose the company to concentrations of credit risk consist primarily of short term cash investments and trade accounts receivable 
as revenues are mainly derived from agreements with major pharmaceutical companies and relationships with drug distributors  and such clients typically have significant cash resources  any credit risk associated with these transactions is considered minimal 
the company operates credit evaluation procedures 
excess cash is invested in short term money market instruments  including bank and building society term deposits and commercial paper from a variety of companies with strong credit ratings 
these investments typically bear minimal risk 
inflation although at reduced levels in recent years  inflation continues to apply upward pressure on the cost of goods and services used by the company 
however  management believes that the net effect of inflation on the company s operations has been minimal during the past three years 
year the company experienced no significant year compliance issues and year issues did not have a material effect on its business  results of operations  or financial condition 
euro conversion on january   the european economic and monetary union emu introduced the euro as the official currency of the participating member countries 
on that date  the currency exchange rates of the participating countries were fixed against the euro 
there is a three year transition to the euro  and at the end of the currency will come into circulation and national currencies will be withdrawn by july the uk did not participate in the emu at the commencement of the third stage on january  and it is uncertain whether or on what terms the uk would be permitted to join at a later date 
there can be no prediction as to whether the uk will participate in the emu or as to the rate at which the pound sterling would be converted into the euro 
furthermore  there can be no prediction as to the likely impact on the us dollar sterling exchange rate of a decision by the uk to participate in the emu 
it is anticipated that the pricing of goods and services will be more transparent through the use of a single currency within the participating member states 
competition is likely to increase with the greater price transparency and removal of exchange rate risk 
in the longer term more general price convergence is likely  assuming the emu leads to greater harmonization of healthcare policies across the participating member states 
shire has sales and marketing operations in the republic of ireland  france  germany  spain and italy and therefore there may be some impact on the company s business and competitive position as a result of the increased price transparency 
the company has reviewed its financial and operating systems and is satisfied that the introduction of the euro will not cause any disruption to the business  and that the systems are in place to receive and make payments in euros 
shire will continue to monitor the uk s stance in relation to participation in the euro and assess the impact of any significant changes in policy 
item a quantitative and qualitative disclosures about market risk shire s principal treasury operations are managed by the group s treasury function based in the uk in accordance with the group s treasury policies and procedures which are approved by shire s board 
as a matter of policy  shire does not undertake speculative transactions which would increase its currency or interest rate exposure 
the company is subject to market risk exposure in the following areas o interest rate market risk the company has cash and cash equivalents on which interest income is earned at variable rates 
the company also has a million credit facility including a million five year revolving credit facility including a million letter of credit facility and a million five year term loan facility 
the applicable interest rate on the credit facility ranges between and over the prime rate of credit suisse first boston or the federal funds rate plus or between and over the london interbank overnight rate  in each case depending on shire s credit rating 
the facility is secured by all material property owned by shire and its subsidiaries and the capital stock of shire s subsidiaries 
if shire s credit rating reaches specified levels  the facility will not be secured 
the facility contains customary covenants and additional maintenance tests that require shire to maintain a minimum net worth  a specified leverage ratio and a specified coverage ratio 
the company has no amounts due in respect of debt denominated in foreign currencies 
as at december  and the company had utilized the million five year term loan facility but no other amounts were drawn in respect of the remaining million five year revolving credit facility 
the million five year term loan is repayable on december  o foreign exchange market risk the group s parent company and a number of subsidiary operations are located outside the us as such  the consolidated financial results are subject to fluctuations in exchange rates  particularly between the british pound and canadian dollar against the us dollar 
the financial statements of foreign entities are translated using the accounting policies described in note of the notes to the consolidated financial statements 
the exposure to foreign exchange market risk is managed by the group s treasury function  using forecasts provided by the operating units 
there have been no significant changes to the company s exposure to market risks during the year ended december  
